Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops innovative products for the effective and safe treatment of rare diseases and unmet medical needs. The companys flagship product, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of angioedema attacks in patients with hereditary angioedema (HAE) and has been approved in the US, Europe, Israel, and South Korea. Its product pipeline consists of recombinant human C1 inhibitor (rhC1INH) for the treatment of pre-eclampsia and acute kidney injury; Leniolisib (CDZ 173) for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); a-Glucosidase for the treatment of Pompe and a-Galactosidase for treatment of Fabrys disease respectively.. It markets and sells its products through distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

Pharming Group NV Key Recent Developments

May 20,2020: Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors
May 14,2020: Pharming Group reports financial results for the first quarter of 2020
Mar 11,2020: Pharming CFO to Step Down
Mar 05,2020: Pharming Group reports strong preliminary financial results for 2019
Oct 24,2019: Pharming Group reports strong interim financial results for the first nine months of 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company
Pharming Group NV - Key Facts
Pharming Group NV - Key Employees
Pharming Group NV - Key Employee Biographies
Pharming Group NV - Major Products and Services
Pharming Group NV - History
Pharming Group NV - Company Statement
Pharming Group NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Pharming Group NV - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Rest of the world (RoW)
Performance
Geographical Segment: The US
Performance
Pharming Group NV - Corporate Strategy
Pharming Group NV - SWOT Analysis
SWOT Analysis - Overview
Pharming Group NV - Strengths
Pharming Group NV - Weaknesses
Pharming Group NV - Opportunities
Pharming Group NV - Threats
Pharming Group NV - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Pharming Group NV, Recent Deals Summary
Section 5 Companys Recent Developments
May 20, 2020: Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors
May 14, 2020: Pharming Group reports financial results for the first quarter of 2020
Mar 11, 2020: Pharming CFO to Step Down
Mar 05, 2020: Pharming Group reports strong preliminary financial results for 2019
Oct 24, 2019: Pharming Group reports strong interim financial results for the first nine months of 2019
Oct 24, 2019: Pharming released from CSL Behring court case
Jul 25, 2019: Pharming reports on financial results for the first half of 2019
Jul 25, 2019: Pharming Group reports strong financial results for the first half of 2019
May 16, 2019: Pharming Group announces interim financial results for the first quarter of 2019
Mar 07, 2019: Pharming Group reports strong preliminary financial results for 2018 including first year of net profit
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Pharming Group NV, Key Facts
Pharming Group NV, Key Employees
Pharming Group NV, Key Employee Biographies
Pharming Group NV, Major Products and Services
Pharming Group NV, History
Pharming Group NV, Subsidiaries
Pharming Group NV, Key Competitors
Pharming Group NV, Ratios based on current share price
Pharming Group NV, Annual Ratios
Pharming Group NV, Annual Ratios (Cont...1)
Pharming Group NV, Annual Ratios (Cont...2)
Pharming Group NV, Interim Ratios
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Pharming Group NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Pharming Group NV, Performance Chart (2015 - 2019)
Pharming Group NV, Ratio Charts
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review

Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Biocartis Group NV (BCART) - Product Pipeline Analysis, 2020 Update

Biocartis Group NV (Biocartis) operates as a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for

USD 750 View Report

X5 Retail Group NV - Strategy, SWOT and Corporate Finance Report

X5 Retail Group NV - Strategy, SWOT and Corporate Finance ReportX5 Retail Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information.

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available